INS and hepatocellular carcinoma: Our study indicated that in people with T2DM and compensated cirrhosis, insulin users showed higher risks of all-cause mortality, cardiovascular events, HCC, decompensated cirrhosis, hepatic failure, and hypoglycemia than insulin nonusers, even after excluding persons with hypoglycemia.